1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
EPS Bio Technology Corp.

EPS Bio Technology Corp.

TTPEX:4183
14.30
TWD
+0.10
(+0.70%)
-1.22EPS
316.54MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
18.46
15.57
20.42
22.45
18.05
17.4
19.3
20.07
20.18
19.47
19.75
18.95
21
17.46
Basic EPS, GAAP
0.46
-1.58
1.77
1.4
0.12
0.66
0.77
1.33
0.78
1.07
0.88
0.73
-0.33
-1.22
Free Cash Flow per Basic Share
1.4
-0.97
2.34
1.63
1.25
-0.14
0.2
3.06
0.84
-0.42
1.92
-1.96
-0.98
-0.51
Dividend per Share
0.58
0.1
- -
0.4
0.82
0.3
0.7
0.7
1.2
0.7
0.98
0.8
0.67
- -
Book Value per Share
10.6
8.92
10.69
11.7
11.92
12.28
12.36
12.99
12.57
12.96
12.86
12.8
11.81
11.23
Tangible Book Value per Share
9.28
7.87
9.86
11.05
11.49
11.96
12.02
12.7
12.35
12.8
12.78
12.72
11.69
11.07
Basic Weighted Avg Shares
21
21
21
21
23
24
24
24
24
24
24
24
24
24
Sales/Revenue/Turnover
384
324
425
467
420
414
459
478
480
463
470
451
500
418
Operating Margin (%)
1.89
-13.13
9.1
8.22
4.14
2.41
5.87
9.52
7.13
4.02
5.33
0.78
-1.3
-4.35
Depreciation Expense
19
22
20
14
14
15
16
18
19
17
15
15
15
16
Net Income, GAAP
9
-33
37
29
3
16
18
32
19
25
21
17
-8
-29
Effective Tax Rate (%)
16.98
- -
13.53
17.05
48.67
11.29
23.21
20.89
20.76
7.64
20.67
2.8
- -
- -
Profit Margin (%)
2.47
-10.13
8.68
6.21
0.65
3.81
4.01
6.64
3.88
5.47
4.46
3.84
-1.57
-6.99
Working Capital
140
113
164
187
223
231
224
244
236
244
241
238
201
185
LT Debt
37
40
34
30
28
26
132
126
121
116
110
104
95
92
Total Equity
220
186
222
243
284
292
294
309
299
308
306
305
281
267
Return on Invested Capital (%)
2.21
- -
12.99
11.65
2.99
2.74
5.64
7.92
5.93
3.4
4.57
1.24
- -
- -
Return on Capital (%)
3.85
- -
14.83
11.02
1.04
5.14
5.44
7.71
4.7
6.39
5.33
4.61
- -
- -
Return on Common Equity (%)
4.28
-16.17
18.08
12.47
1.03
5.49
6.29
10.51
6.13
8.35
6.83
5.67
-2.69
-10.21

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
46
46
46
LT Borrowings
8
7
6
LT Finance Leases
87
86
86
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
24
24
24
Market Capitalization
395
381
317

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
355
318
327
Cash, Cash Equivalents & STI
123
95
132
Accounts Receivable, Net
150
119
106
Inventories
73
95
84
Total Current Liabilities
155
131
142
Payables & Accruals
- -
- -
- -
ST Debt
46
46
46
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.57%
-1.82%
-7.7%
Free Cash Flow
1.69%
-206.78%
-50.02%
Net Income, GAAP
27.13%
-37.07%
-145.45%
Sales/Revenue/Turnover
1.86%
1.05%
10.78%
Total Cash Common Dividend
- -
7.03%
-16.25%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
98
134
103
117
451
2025
120
130
- -
119
500
2026
63
106
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.5
0.34
0.27
-0.37
0.73
2025
0.05
-0.54
- -
-0.11
-0.33
2026
-0.52
-0.06
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.8
2025
- -
- -
- -
- -
0.67
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chen Hui Cho
Full Time Employees
108
Sector
Health technology
Industry
Medical specialties
Address
No. 8, R&D Road III Hsinchu TP Taiwan 30076
IPO Date
Nov 13, 2012
Website
epsbio.com.tw
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
EPS Bio Technology Corp. manufactures and sells original equipment manufacturer and original design manufacturer blood glucose monitoring systems in Taiwan. The company offers diabetic self-monitoring blood glucose systems under the EASYMAX and MDT2 BLE brands; test strips; and wearable blood glucose monitors with NFC and Bluetooth connectivity. Founded in 2006 and headquartered in Hsinchu Science Park, Hsinchu City, Taiwan, EPS Bio Technology operates primarily in the medical devices sector, serving diabetes management markets with a workforce of approximately 116 employees focused on research and development.